Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05780463 · ClinicalTrials.gov registry record · Phase 3
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
A Phase 3 study of COVID-19, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 485
- Enrollment target
- 20
- Study locations
NCT05780463 is a Phase 3 study of COVID-19 that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 485 participants, below the 55,212-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT05780463, a Phase 3 study of COVID-19, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 485 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either MP0420 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H5.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MP0420
- BIOLOGICAL Remdesivir
Study Locations (20)
California
- Velocity Chula Vista (Site 080-034), 752 Medical Center Ct., Ste. 304 - Chula Vista
- Community Regional Medical Center (Site 203-005), 2823 Fresno Street - Fresno
- Velocity San Diego (Site 080-035), 5565 Grossmont Center Drive, Building 2, Suite 1 - La Mesa
- VA Long Beach Healthcare System (Site 074-026), 5901 East 7th Street (09/151-M2) - Long Beach
- Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd. - Los Angeles
- Ronald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza - Los Angeles
- Sacramento VA Medical Center (Site 074-023), 10535 Hospital Way - Mather
- Hoag Memorial Hospital Presbyterian (Site 080-026), One Hoag Drive - Newport Beach
- UC Davis Health (Site 203-004), 2315 Stockton Blvd. - Sacramento
- VA San Diego Healthcare System (Site 074-016), 3350 La Jolla Village Drive - San Diego
- UCSF Medical Center at Mount Zion (Site 203-007), 1600 Divisadero St. - San Francisco
- San Francisco VAMC (Site 074-002), 4150 Clement St. - San Francisco
- UCSF Medical Center (Site 203-001), Moffitt-Long Hospital, 505 Parnassus Ave. - San Francisco
- Stanford University Hospital & Clinics (Site 203-003), 300 Pasteur Dr. - Stanford
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Site 066-002), 1124 W. Carson Street, CDCRC Building - Torrance
Arizona
- Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue - Tucson
- Southern Arizona VA Healthcare System (Site 074-009), 3601 S. 6th Ave. - Tucson
Colorado
- University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue - Aurora
- Denver Public Health (Site 017-004), 660 Bannock St., MC2600 (Infectious Disease Clinic) - Denver
Connecticut
- West Haven VA Medical Center (Site 025-007), 950 Campbell Avenue - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2023-06-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05780463
The ClinicalTrials.gov registry entry for NCT05780463 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 485 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,212-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05780463 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT05780463 about?
NCT05780463 is a clinical study titled "MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)". This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either MP0420 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment ...
What is the current status of trial NCT05780463?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 485 participants. The study started on 2021-06-11. Estimated completion is 2023-06-08.
What conditions does trial NCT05780463 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05780463?
The interventions under investigation include: Placebo (DRUG), MP0420 (DRUG), Remdesivir (BIOLOGICAL).
Who is sponsoring clinical trial NCT05780463?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05780463 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Immunogenicity of NVX-CoV2705
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.